Hematologic changes in a patient with heparin-induced thrombocytopenia who underwent cardiopulmonary bypass after ancrod defibrinogenation.
Spiess
B D
BD
Department of Anesthesia, University of Washington, Seattle 98195, USA.
Gernsheimer
T
T
Vocelka
C
C
Chandler
W L
WL
Benak
A
A
Joy
J V
JV
Wright
I
I
Hofer
B O
BO
D000368:Aged; D000721:Ancrod / Q000627:therapeutic use*; D000925:Anticoagulants / Q000009:adverse effects*; D002315:Cardiopulmonary Bypass; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D013921:Thrombocytopenia / Q000139:chemically induced*; D010959:Tissue Plasminogen Activator / Q000378:metabolism
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006493:Heparin; D000721:Ancrod; D010959:Tissue Plasminogen Activator